Medtronic Boosts Cardiac Ablation Portfolio with Strategic Investments in ICE Catheter Technologies
Summary
Medtronic announced strategic investments in two privately held companies, Beluga Medical and CardioACC, which develop intracardiac echocardiography (ICE) catheter technologies. These investments aim to integrate ICE into Medtronic's Affera™ mapping and ablation system, bolstering its cardiac ablation business and leadership in electrophysiology. This move follows the company's strong Q4 earnings report released earlier today and reinforces its strategy to expand high-growth product portfolios.
At the time of this announcement, MDT was trading at $73.30 on NYSE in the Life Sciences sector, with a market capitalization of approximately $94.7B. The 52-week trading range was $73.31 to $106.33. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.